Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16867594 | 1.00 | KMT2A (0.56) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31217953 | 0.99 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29609426 | 0.99 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29101959 | 0.95 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29233234 | 0.92 | KMT2A (0.53) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL38657876 | 0.91 | KMT2A (0.62) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL30620554 | 0.89 | KMT2A (0.61) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL20628608 | 0.88 | KMT2A (0.46) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL27432171 | 0.88 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31217947 | 0.87 | KMT2A (0.48) | KMT2AEPHX2FABP5FABP7OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024235132-A9 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2024235128-A9 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4508061-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024235132-A1 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235128-A1 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-20240026030-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-25 | — | — | US | disclosed |
| WO-2024008102-A1 | LINKER FOR CONJUGATION | WUXI XDC (SHANGHAI) CO., LTD. (CN) | 2024-01-11 | — | — | WO | disclosed |
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| WO-2023198195-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2023-10-19 | — | — | WO | disclosed |
| EP-4115909-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026030-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | KMT2A 386/4885EPHX2 2136/4885FABP5 2840/4885 |
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | STING1, CGAS, TLR9 | KMT2A 2926/4885EPHX2 1097/4885FABP5 3438/4885 |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | KMT2A 2191/4885EPHX2 3659/4885FABP5 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.